In pancreatic adenocarcinoma, KRAS mutations were found in 85.8% of cases, of which Q61R mutations were found in 1.2%, which was very rare with a frequency of about 1.0% of all PDAC cases. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.